Mechanistic studies in CAPS mouse models and clinical experience with IL‐1‐targeted therapies both suggest that excessive IL‐1β production is the key mediator of systemic inflammatory pathology in CAPS, with evidence for additional roles of IL‐18 and pyroptosis.18, 60, 61. The gene discussed is IL1B; the disease is cryopyrin-associated periodic syndrome.